Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BORTEZOMIB Cause Disseminated intravascular coagulation? 78 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 78 reports of Disseminated intravascular coagulation have been filed in association with BORTEZOMIB (bortezomib). This represents 0.2% of all adverse event reports for BORTEZOMIB.

78
Reports of Disseminated intravascular coagulation with BORTEZOMIB
0.2%
of all BORTEZOMIB reports
61
Deaths
42
Hospitalizations

How Dangerous Is Disseminated intravascular coagulation From BORTEZOMIB?

Of the 78 reports, 61 (78.2%) resulted in death, 42 (53.8%) required hospitalization, and 30 (38.5%) were considered life-threatening.

Is Disseminated intravascular coagulation Listed in the Official Label?

Yes, Disseminated intravascular coagulation is listed as a known adverse reaction in the official FDA drug label for BORTEZOMIB.

What Other Side Effects Does BORTEZOMIB Cause?

Plasma cell myeloma (6,683) Off label use (4,754) Neuropathy peripheral (4,067) Drug ineffective (2,730) Diarrhoea (2,244) Thrombocytopenia (2,082) Death (2,025) Pneumonia (2,020) Fatigue (1,757) Neutropenia (1,530)

What Other Drugs Cause Disseminated intravascular coagulation?

PREDNISOLONE (362) METHOTREXATE (347) DEXAMETHASONE (323) METHYLPREDNISOLONE (307) NIVOLUMAB (305) CYCLOPHOSPHAMIDE (286) TACROLIMUS (278) PREDNISONE (277) VINCRISTINE (245) OXALIPLATIN (231)

Which BORTEZOMIB Alternatives Have Lower Disseminated intravascular coagulation Risk?

BORTEZOMIB vs BOSENTAN BORTEZOMIB vs BOSENTAN\BOSENTAN BORTEZOMIB vs BOSULIF BORTEZOMIB vs BOSUTINIB BORTEZOMIB vs BOTOX

Related Pages

BORTEZOMIB Full Profile All Disseminated intravascular coagulation Reports All Drugs Causing Disseminated intravascular coagulation BORTEZOMIB Demographics